29,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB) are clinically and neuropathologically highly related α-synucleinopathies that collectively constitute the second leading cause of neurodegenerative dementias. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Thalamic atrophy is a common feature across all forms of FTD but little is known about specific nuclei involvement. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
The authors report on clinical features and mortality rates in a group of 149 patients with apparent idiopathic parkinsonism starting before the age of 40 years. 1 key finding →
Participants: 149 Evidence: low
Full summary, score breakdown and related studies → Original source
Parkinson's disease (PD) is a multisystem neurodegenerative disorder. 2 key findings →
Participants: 101 Evidence: low
Full summary, score breakdown and related studies → Original source
Thirty cases of diffuse Lewy body disease (DLBD) have been reported, primarily by neuropathologists, but an associated clinical syndrome has not been clearly defined. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
In contrast to clinic-based samples, the most frequently occurring complications of PD in this community-based sample were axial features such as postural instability with falls. 5 key findings →
Participants: 124 Evidence: low
Full summary, score breakdown and related studies → Original source
Detailed molecular pathology studies and clinicopathological phenotyping of familial amyotrophic lateral sclerosis (FALS) with characterised mutations in the gene encoding Cu/Zn superoxide dismutase (SOD1) will yield important insights into the pathogenesis of motor neuron degeneration. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
A factor analysis revealed 3 dimensions of burden: role strain, personal strain, and worry about performance. 5 key findings →
Participants: 611 Evidence: low
Full summary, score breakdown and related studies → Original source
Cerebral small vessel disease (cSVD) comprises pathological processes of the small vessels in the brain that may manifest clinically as stroke, cognitive impairment, dementia, or gait disturbance. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Progressive cerebrovascular atherosclerosis and consecutive stroke are among the most common causes of dementia. 1 key finding →
Participants: 186 Evidence: low
Full summary, score breakdown and related studies → Original source
This case highlights potential long-term neurodegenerative outcomes in retired professional National Football League players subjected to repeated mild traumatic brain injury. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
The accumulation of pathological misfolded tau is a feature common to a collective of neurodegenerative disorders known as tauopathies, of which Alzheimer's disease (AD) is the most common. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Tauopathies are neurodegenerative diseases characterized by aberrant forms of tau protein accumulation leading to neuronal death in focal brain areas. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Neurodegenerative diseases, including Alzheimer's Disease (AD) and Parkinson's Disease (PD) are common complications of diabetes, arising from insulin resistance, inflammation, and other pathological processes in the central nervous system. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We find that IRAs can cross the BBB by two separate processes; one that is fast and one that is slow. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Neuropsychiatric symptoms are common in patients with PDD. 3 key findings →
Participants: 537 Evidence: low
Full summary, score breakdown and related studies → Original source
The phenomena of visual hallucinations associated with PD, while not fully explained, are unique enough to be of interest to all neurologists and neuroscientists. 5 key findings →
Participants: 214 Evidence: low
Full summary, score breakdown and related studies → Original source
Standard validity indices showed that the LARS is sensitive and capable of distinguishing between apathy and depression. 2 key findings →
Participants: 159 Evidence: low
Full summary, score breakdown and related studies → Original source
Parkinson's disease is a recognisable clinical syndrome with a range of causes and clinical presentations. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
No significant differences in p-tau217, GFAP and NfL level were observed between groups (pFDR > 0.08). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
It is unclear whether Alzheimer disease pathology drives cognitive decline in Parkinson disease (PD) patients carrying GBA1 variants. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia with Lewy bodies (DLB), a synucleinopathy, is the second most common form of dementia after Alzheimer's disease (AD). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
High CSF p-tau and low ratios of Aβ(1-42)/Aβ(1-40) and Aβ(1-42)/Aβ(1-38), respectively, were specific for AD. 5 key findings →
Participants: 25 Evidence: low
Full summary, score breakdown and related studies → Original source
The main objective was to investigate the acetylcholinesterase E (AChE) activity in the cerebrospinal fluid (CSF) of patients with three common dementia disorders. 3 key findings →
Participants: 17 Evidence: low
Full summary, score breakdown and related studies → Original source
Vascular factors are thought to contribute to the development of disease pathology in neurodegenerative dementia such as Alzheimer's disease (AD). 1 key finding →
Participants: 47 Evidence: low
Full summary, score breakdown and related studies → Original source
10 of the 2,718 studies in this tag that have a study page, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 29,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 29,780 records, built mostly from automated pulls of Europe PMC (63.8% of the library) and OpenAlex (17.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,037 records (3.5% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →